Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men or women at least 18 years of age or older.~2. Patients must have a confirmed and documented RRMS diagnosis~3. Patients must be ambulatory with a Kurtzke EDSS score of 0 to 5.5 at screening visit.~4. Patients must be in a stable neurological condition, relapse-free and free of any corticosteroid treatment 30 days prior to randomization.~5. Women of child-bearing potential must have a negative urine pregnancy test at screening visit and must practice an acceptable method of birth~6. Patients must be able to sign and date a written informed consent prior to entering the study.~7. Patients must be willing and able to comply with the protocol requirements for the duration of the study.~Exclusion Criteria~1. Patient had any contraindication to Copaxone therapy.~2. Previous use of Copaxone 40 mg/mL three times per week.~3. Patients with progressive forms of MS.~4. Patients with neuromyelitis optica.~5. Use of experimental or investigational drugs, and/or participation in drug clinical studies within the 6 months prior to screening.~6. Patients who have been treated with; immunosuppressive medications, immunoglobulins and/or monoclonal antibodies, alemtuzumab, cladribine, cyclophosphamide or mitoxantrone at any time~7. Chronic (more than 30 consecutive days) systemic (IV, PO or IM) corticosteroid treatment within 6 months prior to screening visit.~8. Pregnancy or breastfeeding.~9. Clinically significant or unstable medical or surgical condition that would preclude safe and complete study participation~10. Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals~    * other criteria may apply, please contact the investigator for more information

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Copaxone® 40 mg/mL (Type: EXPERIMENTAL): Subcutaneous Injections 40 mg/mL Three Times a Week for the core period which last 6 months. In the extension period patient are administered Copaxone® 40 mg/mL for months 7 - 12.
- Copaxone® 20 mg/mL (Type: ACTIVE_COMPARATOR): Subcutaneous Injections 20 mg/mL Daily for the core period which last 6 months. In the extension period patient are administered Copaxone® 40 mg/mL for months 7 - 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).